TR200002427T2 - New compounds and their use as positive ampa receptor modulators. - Google Patents

New compounds and their use as positive ampa receptor modulators.

Info

Publication number
TR200002427T2
TR200002427T2 TR2000/02427T TR200002427T TR200002427T2 TR 200002427 T2 TR200002427 T2 TR 200002427T2 TR 2000/02427 T TR2000/02427 T TR 2000/02427T TR 200002427 T TR200002427 T TR 200002427T TR 200002427 T2 TR200002427 T2 TR 200002427T2
Authority
TR
Turkey
Prior art keywords
ampa receptor
new compounds
receptor modulators
positive ampa
positive
Prior art date
Application number
TR2000/02427T
Other languages
Turkish (tr)
Inventor
Larsen Mogens
Varming Thomas
Mathiesen Claus
Scheel-Kruger Jorgen
M. Olsen Gunnar
Holm Johansen Tina
Ostergaard Nielsen Elsebet
Haahr Gouliaev Alex
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of TR200002427T2 publication Critical patent/TR200002427T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Bu bulus, kesik hat ile temsil edilen bagin bir tekil veya çift bag olabildigi veya mevcut olmayabildigi; ve bagin mevcut olmamasi durumunda nitrojenin hidrojen ve R2 ile ikameli oldugu; X' in SO2 veya C=O veya CH2 oldugu; Y' nin -CH(R4)-, -(R4)-veya -N(R4)-CH2-,O oldugu; ve R2,R3,R4,R5,R6,R7, ve R8' in anlamlarinin basvurudaki gibi oldugu genel formül Formül (I)ile ifade edilebilen bir bilesigi sunmaktadir. Bu bilesikler, AMPA reseptörünün pozitif modülatörleri olarak faydalidir.This invention may or may not be present in a single or double bond, represented by a broken line; and nitrogen is substituted with hydrogen and R2 if the bond is absent; X is SO2 or C = O or CH2; Y is -CH (R4) -, - (R4) -or -N (R4) -CH2-, O; and the general formula where the meanings of R2, R3, R4, R5, R6, R7, and R8 are as in the application presents a compound that can be expressed by Formula (I). These compounds are useful as positive modulators of the AMPA receptor.

TR2000/02427T 1998-02-18 1999-02-18 New compounds and their use as positive ampa receptor modulators. TR200002427T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK22698 1998-02-18

Publications (1)

Publication Number Publication Date
TR200002427T2 true TR200002427T2 (en) 2001-01-22

Family

ID=8091151

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02427T TR200002427T2 (en) 1998-02-18 1999-02-18 New compounds and their use as positive ampa receptor modulators.

Country Status (17)

Country Link
EP (1) EP1071426A2 (en)
JP (1) JP2002504481A (en)
CN (1) CN1293665A (en)
AU (1) AU751384B2 (en)
CA (1) CA2320354A1 (en)
EE (1) EE200000468A (en)
HU (1) HUP0101280A3 (en)
IL (1) IL137720A0 (en)
IS (1) IS5581A (en)
NO (1) NO20004121L (en)
NZ (1) NZ506251A (en)
PL (1) PL342843A1 (en)
RU (1) RU2214405C2 (en)
SK (1) SK11892000A3 (en)
TR (1) TR200002427T2 (en)
WO (1) WO1999042456A2 (en)
ZA (1) ZA991301B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
DE10004572A1 (en) 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma New positive allosteric AMPA receptor modulators (PAARM), processes for their production and their use as medicines
FR2812291B1 (en) * 2000-07-28 2002-12-13 Adir NOVEL BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN1314351A (en) * 2001-03-22 2001-09-26 刘志红 Process for synthesizing quinazolone and quinazolone compound with anti-cancer function
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
AU2002320841B2 (en) 2001-06-14 2008-02-28 Merck Sharp & Dohme B.V. (Pyrido/thieno)-[f]-oxazepin-5-one derivatives as positive modulators of the AMPA receptor
CA2458388A1 (en) 2001-10-10 2003-04-17 Neurosearch A/S Novel benzothiazine derivatives, their preparation and use
US7799913B2 (en) * 2001-11-26 2010-09-21 Cortex Pharmaceuticals, Inc. Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
FR2833955B1 (en) 2001-12-21 2004-01-30 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2833950B1 (en) * 2001-12-21 2005-12-16 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2833956B1 (en) 2001-12-21 2004-01-30 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2854634B1 (en) 2003-05-05 2005-07-08 Servier Lab NOVEL THIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2856065B1 (en) * 2003-06-13 2005-08-19 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2856064B1 (en) * 2003-06-13 2005-08-19 Servier Lab NOVEL BENZOTHIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
RU2006102869A (en) 2003-07-02 2007-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Arylamino-substituted quinazolinone compounds
AU2004270161A1 (en) 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
FR2865474B1 (en) * 2004-01-26 2008-06-13 Servier Lab NOVEL FLUORINATED BENZOTHIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2877338B1 (en) 2004-11-03 2007-01-26 Servier Lab NOVEL BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2877342B1 (en) * 2004-11-03 2007-01-26 Servier Lab NOVEL BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2879201B1 (en) * 2004-12-10 2007-02-16 Servier Lab NOVEL BENZOTHIAZINE AND BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
DE602006004964D1 (en) 2005-02-10 2009-03-12 Bristol Myers Squibb Co DIHYDROCHINAZOLINONE AS 5HT MODULATORS
JP2008531579A (en) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド Nitric oxide enhanced diuretic compounds, compositions and methods of use
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
ES2374995T3 (en) 2007-01-03 2012-02-23 Les Laboratoires Servier COMPOSITE OF [1,2,3] -BENZOTRIAZINONE 3-REPLACED TO IMPROVE GLUTAMATERGIC SYNAPTIC RESPONSES.
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EA200901546A1 (en) 2007-05-17 2010-04-30 Кортекс Фармасеутикалс, Инк. DESIGNED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
SG163526A1 (en) 2007-08-10 2010-08-30 Cortex Pharma Inc Bicyclic amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
FR2933698A1 (en) 2008-07-09 2010-01-15 Servier Lab NOVEL CYCLOALKYLATED BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2943342B1 (en) 2009-03-20 2011-03-04 Servier Lab NOVEL BENZOTHIADIAZEPINES DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
SI2464645T1 (en) 2009-07-27 2017-10-30 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
FR2955107B1 (en) 2010-01-08 2012-03-02 Servier Lab NOVEL THIOCHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2955106B1 (en) 2010-01-08 2011-12-23 Servier Lab NOVEL CYCLOPROPYLATED BENZOTHIADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN102958919A (en) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 Novel tetrahydroquinoline derivatives
CN103096977B (en) 2010-07-02 2017-02-15 吉利德科学公司 Fused heterocyclic compounds as ion channel modulators
FR2964969B1 (en) * 2010-09-16 2012-08-24 Servier Lab NOVEL DIHYDROBENZOXATHIAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1402905B1 (en) * 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia DERIVATIVES OF 1,2,4-BENZOTIADIAZIN 1,1-DIOXIDE, THEIR PREPARATION AND THEIR USE AS ALLOSTERIC MODULATORS OF THE AMPA RECEPTOR.
CN103649056B (en) 2011-05-10 2016-04-27 吉利德科学公司 As the condensed heterocyclic compouds of ion channel modulators
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
CN102977054A (en) * 2012-12-12 2013-03-20 中国药科大学 Application of selective alpha2A receptor stimulant in treating alzheimer disease
SG11201509057UA (en) 2013-05-30 2015-12-30 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
JO3316B1 (en) 2013-05-30 2019-03-13 Lilly Co Eli 3,4-dihydroisoquinolin-2(1h)-yl compounds
CN103275016B (en) * 2013-06-04 2015-03-11 温州医科大学附属第二医院 Synthetic method of 2-subsituted quinazoline compounds
BR112015031249A2 (en) 2013-06-13 2017-07-25 Veroscience Llc treatment method, method for treating a metabolic disorder or a key element thereof, method for normalizing a daily dopamine release rate in the sumn, method for stimulating dopamine release from dopaminergic neurons in an individual's sumn and pharmaceutical composition
CN103319381B (en) * 2013-06-14 2014-08-27 湖州康企药业有限公司 Preparation method of high-purity fine sulfanilamide
CN103772296B (en) * 2013-12-19 2015-06-17 安徽师范大学 Synthesis method for quinazoline derivative
EP3227263B1 (en) 2014-12-01 2019-04-10 Idorsia Pharmaceuticals Ltd Cxcr7 receptor modulators
CN105294599B (en) * 2015-09-17 2017-09-22 三峡大学 A kind of diazthines compound and its asymmetric synthetic method
CN106946920A (en) * 2017-04-05 2017-07-14 泰力特医药（湖北）有限公司 A kind of preparation method of 4 amino phenyl boronic acid derivative
WO2020253862A1 (en) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 Nitrogen-containing aryl phosphorus oxide derivative, preparation method therefor and use thereof
RU2726456C1 (en) * 2019-10-02 2020-07-14 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Hepatitis b virus (hbv) inhibitor
CN111100042B (en) * 2019-11-18 2022-05-31 苏州诚和医药化学有限公司 Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN111018750B (en) * 2019-12-19 2022-05-27 苏州诚和医药化学有限公司 Novel preparation method of 2, 3-dimethoxy-5-sulfamide benzoic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296964A (en) *
US3275625A (en) * 1966-09-27 Derivatives of
FR1217929A (en) * 1958-03-03 1960-05-06 Ciba Geigy Process for the preparation of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide and its salts
GB863474A (en) * 1958-08-13 1961-03-22 Knud Abildgaard Benzothiadiazine derivatives and their preparation
DE1125938B (en) * 1960-02-12 1962-03-22 Thomae Gmbh Dr K Process for the preparation of 7-sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes
GB946864A (en) * 1960-05-06 1964-01-15 Knud Abildgaard Method for the production of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US3419552A (en) * 1961-04-12 1968-12-31 Lilly Co Eli Preparation of substituted dihydrobenzothiadiazine-1,1-dioxides
CH475269A (en) * 1962-04-19 1969-07-15 Hans Voigt Chem Pharm Fabrik D Process for the preparation of 7-sulfonamido-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxydes
US3351595A (en) * 1962-12-07 1967-11-07 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2h-1, 2, 4-benzothiadiazine-1, 1-dioxide
US3311620A (en) * 1963-05-31 1967-03-28 Stanley C Bell Fused ring benzothiadiazines
US3277086A (en) * 1964-07-07 1966-10-04 American Home Prod 1, 2, 4-benzothiadiazine 1, 1-dioxides having a heterocyclic ring fused to the "b" face thereof
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
AU3957093A (en) * 1992-04-15 1993-11-18 Rhone-Poulenc Rorer S.A. 3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxyl ic acid derivatives, preparation thereof and drugs containing same
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
FR2722502B1 (en) * 1994-07-12 1996-08-23 Adir NOVEL BENZOTHIADIAZINE DERIVATIVE, ITS PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
NZ331549A (en) * 1996-01-29 2000-09-29 Univ California Compounds useful in treating sexual dysfunction
AU4345297A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor

Also Published As

Publication number Publication date
RU2214405C2 (en) 2003-10-20
NO20004121D0 (en) 2000-08-17
AU751384B2 (en) 2002-08-15
IL137720A0 (en) 2001-10-31
SK11892000A3 (en) 2001-02-12
NZ506251A (en) 2003-01-31
CN1293665A (en) 2001-05-02
EP1071426A2 (en) 2001-01-31
HUP0101280A2 (en) 2001-10-28
CA2320354A1 (en) 1999-08-26
ZA991301B (en) 1999-09-13
NO20004121L (en) 2000-10-17
EE200000468A (en) 2002-04-15
PL342843A1 (en) 2001-07-16
AU2512399A (en) 1999-09-06
HUP0101280A3 (en) 2003-02-28
WO1999042456A3 (en) 1999-10-07
WO1999042456A2 (en) 1999-08-26
IS5581A (en) 2000-08-04
JP2002504481A (en) 2002-02-12

Similar Documents

Publication Publication Date Title
TR200002427T2 (en) New compounds and their use as positive ampa receptor modulators.
TR200102800T2 (en) New compounds.
TR199901674T2 (en)
ATE37375T1 (en) PHOSPHONYL HYDROXYACYL AMINO ACID DERIVATIVES AND THEIR USE AS ANTIHYPERTENSIVES.
ES2163638T3 (en) NEW N- (1-RENT-5-PHENYL-2,3,4,5-TETRAHYDRO-1H-BENZO (B) (1,5) DIACEPIN-3-IL) ACETAMIDS.
TR199700803T1 (en) Novel dipeptidic amidines as thrombin-inhibitors.
SE9702773D0 (en) Novel compounds
MX9101957A (en) AMINOSULFONYL CARBAMATES
TR199801399T2 (en) This is a 19-month-old train.
TR199801734T2 (en) New arylglycinamide derivatives, production methods.
ES476343A1 (en) Cyclopentan-1-amines
TR200201684T2 (en) Phenylpiperazinyl derivatives
ATE165972T1 (en) 2(5H)-FURANONES SUBSTITUTED IN POSITION 3 AS CA 2+ ANTAGONISTS AND ANTI-INFLAMMATORY AGENTS
DE69626981D1 (en) N- (2-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl) -3-AMIDE
TR200400857T4 (en) Derivatives and analogs of new galantamine
NZ333281A (en) Asymmetric stilbene compounds for use as sun protection agents
TR200100603T2 (en) Pyrazine compounds
DE59707524D1 (en) 1,3-BIS (N-LACTAMYL) PROPANES AND THEIR PHARMACEUTICAL AND COSMETIC USE
TR199900363T2 (en) Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists.
ES8707525A1 (en) Isoindolinyl-alkyl-piperazines
TR200001222T2 (en) New tetracyclics, the process for their manufacture and pharmaceutical preparations containing these compounds.
TR200402650T4 (en) New positive allosteric ampa-receptor modulators (paarms), methods for their manufacture and their use as pharmaceuticals
ES2194102T3 (en) NEW N- (2,4-DIOXO-2,3,4,5-TETRAHIDRO-1H-1,5-BENZODIAZEPIN-3-IL) -3-AMIDAS.
TR200103801T2 (en) Processes for the preparation of new substituted propenone derivatives
MX9603199A (en) Endotheline receptors antagonists.